XML 50 R39.htm IDEA: XBRL DOCUMENT
v3.25.3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 24 Months Ended
--- | --- | --- | ---
Sep. 28, 2025 | Sep. 29, 2024 | Sep. 28, 2025 | Sep. 29, 2024 | Sep. 28, 2025
Restructuring charges/(credits): |  |  |  |  |  |
Employee terminations |  | $ 124 | $ 25 | $ 360 | $ 1,009 |
Asset impairments |  | 111 | 111 | 328 | 177 |
Exit costs |  | 2 | 82 | 96 | 145 |
Restructuring charges/(credits) | [1] | 237 | 217 | 784 | 1,331 |
Transaction costs | [2] | 0 | 0 | 0 | 5 |
Integration costs and other | [3] | 49 | 96 | 162 | 333 |
Restructuring charges and certain acquisition-related costs |  | 286 | 313 | 945 | 1,669 |
Inventory write-offs––recorded in Cost of sales |  | 33 | 0 | 33 | 0 |
Additional depreciation––asset restructuring | [4] | 4 | 8 | 11 | 16 |
Implementation costs | [5] | 105 | 75 | 234 | 238 |
Total costs associated with acquisitions and cost-reduction/productivity initiatives |  | 423 | 398 | 1,150 | 1,930 |
Biopharma [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Restructuring charges/(credits) |  | 240 | 141 | 451 | 1,200 |
Biopharma [Member] | Manufacturing Optimization Program [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Restructuring charges/(credits) |  | 117 |  | (295) | 1,300 |
Biopharma [Member] | Realigning Our Cost Base Program [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Restructuring charges/(credits) |  | 107 |  | 669 | (69) | $ 2,600
Other (income)/deductions––net [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net |  | (6) | 2 | (74) | 7 |
Cost of sales [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Additional depreciation––asset restructuring | [4] | 3 | 6 | 10 | 11 |
Implementation costs | [5] | 26 | 30 | 72 | 95 |
Selling, informational and administrative expenses [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Additional depreciation––asset restructuring | [4] | 0 | 2 | 0 | 5 |
Implementation costs | [5] | 26 | 13 | 46 | 77 |
Research and development expenses [Member] |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |
Additional depreciation––asset restructuring | [4] | 1 | 0 | 1 | 0 |
Implementation costs | [5] | $ 53 | $ 33 | $ 116 | $ 66 |
[1] | Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program), (ii) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program), (iii) charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and (iv) charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost Base Program). For the nine months ended September 28, 2025 and September 29, 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[2] | Represents external costs for banking, legal, accounting and other similar services.
[3] | Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[4] | Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] | Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

X
- Definition This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services. + References No definition available. + Details
Name: | pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. + References No definition available. + Details
Name: | pfe_ImplementationCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Restructuring, Asset Impairment Charges + References No definition available. + Details
Name: | pfe_RestructuringAssetImpairmentCharges
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Restructuring Charges, Acquisition Related Costs and Implementation Costs + References No definition available. + Details
Name: | pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. + References No definition available. + Details
Name: | pfe_RestructuringChargesAndAcquisitionRelatedCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for integration-related cost incurred in connection with business combination. Includes system integration and conversion costs; severance and other employee-related costs; restructuring and other post-combination costs. Excludes acquisition-related cost incurred to effect business combination; cost to issue debt or equity securities; and cost related to acquisition of asset. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7 + Details
Name: | us-gaap_BusinessCombinationIntegrationRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_BusinessExitCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of net periodic benefit cost (credit) for defined benefit plan. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details
Name: | us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details
Name: | us-gaap_InventoryWriteDown
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RestructuringChargesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan. + References No definition available. + Details
Name: | us-gaap_RestructuringReserveAcceleratedDepreciation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_SeveranceCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringPlanAxis=pfe_ManufacturingOptimizationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringPlanAxis=pfe_RealigningOurCostBaseProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |